OS Therapies has secured $4,200,000 in investment capital. The funding will support the clinical-stage research company as it advances its therapeutic treatments for Osteosarcoma, Breast Cancer, and other solid tumors. This financial injection marks a significant step for the company in its mission to develop innovative oncology solutions.
The company operates with two primary platform technologies. OST-HER2, one of its lead candidates, is currently completing a Phase IIb clinical trial in the fourth quarter of 2024, having shown significantly improved Event Free Survival (EFS) and early Overall Survival (OS). Its second platform, OST-tADC, is a novel pre-clinical pH-sensitive Drug Conjugate. This technology utilizes proprietary silicon to encapsulate and link multiple payloads, delivering and activating them specifically when exposed to the acidic environment of cancer cells, where the silicon dissolves.
The newly raised capital is expected to accelerate the development of these promising therapeutic programs. OS Therapies plans to allocate the funds towards advancing its ongoing clinical trials, furthering its research and development efforts, and strategically expanding its operational capabilities to support future growth. This investment is crucial for propelling the company's pipeline through key development milestones.
This funding round underscores the perceived potential of OS Therapies' innovative approaches to cancer treatment. The company remains committed to its objective of progressing its pipeline and bringing its advanced therapies closer to patients in need. OS Therapies aims to continue its trajectory of growth, focusing on making a meaningful impact in the field of oncology by addressing critical unmet needs in cancer therapy.
